The focus of perioperative pain management should be to attempt to minimise the nociceptive input and reduce the risk of transition to central sensitisation. Gabapentinoids are being increasingly used as adjuncts for management of perioperative pain. Although gabapentinoids are classed as calcium channel blockers, their mechanisms of action are poorly understood. The analgesic effect in neuropathic pain is well evidenced but the role in postoperative pain is less certain. Medline and EMBASE database searches were conducted to identify studies relating to mechanisms of action and effects in experimental animal models of inflammatory and postoperative pain and human models of experimental pain. The effects of gabapentinoids may be attributed to depression of dorsal horn sensitivity through a multitude of mechanisms.
The gabapentinoids, pregabalin and gabapentin, have been the cornerstone of pharmacological management of neuropathic pain. 1 Despite the widespread use in neuropathic pain, the precise mechanism of action is uncertain. The effect of gabapentinoids in pain are assumed to be because of direct inhibition of voltage gated Ca 2þ channels by binding to its a2d-1 subunit resulting in reduction of presynaptic Ca 2þ influx and subsequent release of excitatory neurotransmitters such as glutamate. This assumption is not correct as calcium currents are not consistently reduced by acute application of gabapentinoids. 2 Despite this, most studies show that gabapentinoids inhibit release of neurotransmitters in neuronal tissues. 2 This review explores the possible mechanisms by which gabapentinoids inhibit neurotransmitter release despite the lack of acute effect on Ca 2þ currents. This review has also sought to identify the analgesic mechanisms unrelated to the direct inhibition of neurotransmitter release at the dorsal horn. Although there is good evidence for the effect on neuropathic pain, the role in postoperative pain is less certain. Gabapentinoids are being increasingly used in the perioperative period as part of multimodal analgesia. 3 However, the evidence to support its use in postoperative pain is limited because of the poor quality of evidence from clinical trials. 4 This review sought to determine the effects of gabapentinoids in animal models of postoperative and inflammatory pain and in human pain models. The implications for clinical practice are discussed.
Methods
Medline and EMBASE database searches were conducted to identify studies relating to mechanisms of action and effects in experimental pain models (Appendix A). The reference lists of selected articles were explored for additional studies. Only manuscripts published in English were included. The level of evidence could not be graded as most studies were exploratory in nature. Various themes relating to mechanisms were identified and selected studies described.
Nociceptive pathways, voltage-gated calcium channels, and the a2d subunit
Nociceptors are pseudo-unipolar: the cell bodies are located in the dorsal root ganglion (DRG), a single process bifurcates into a central axon that project to second-order neurons and local interneurons in the dorsal horn of the spinal cord, and a peripheral axon travels through the spinal nerve to the periphery. 5 After nerve injury or inflammation, the stimulation threshold of nociceptors is reduced. The sensitised nociceptors are activated by minimal stimulida process known as peripheral sensitisation that causes primary hyperalgesia. The action potentials that are transmitted to the nociceptors are relayed to the spinal dorsal horn through the central axon and to the periphery through the peripheral axon. This causes membrane depolarisation, activation of voltage-gated calcium channels (VGCCs) and calcium influx, triggering release of glutamate as a major neurotransmitter along with neuromodulators such as substance P, calcitonin gene-related peptide, and brain-derived neurotrophic factor. These are released both peripherally at the site of inflammation and in the dorsal horn, to produce an excitatory signal at the post synaptic targets. 5 The effects on the dorsal horn neurons of the spinal cord are mediated by the postsynaptic glutamate receptorsdaamino-3-hydroxy-5-methyl-4-isoxazolepropionate, N-methyl-D-aspartate and kainite. 6 Many neurons also regulate neurotransmitter release through expressing presynaptic glutamate receptors. 7 The excitatory interneurons in the dorsal horn are also glutamatergic. The enhanced release of glutamate in the dorsal horn of the spinal cord causes increased activation of postsynaptic nociceptive neurons resulting in central sensitisation and secondary hyperalgesia. The spinal cord is clearly an important site for modulation of central sensitisation, as it receives multiple inputs from peripheral neurons, interneurons, astrocytes, microglia, and descending modulatory controls. 8 Generally, this process of sensitisation reverts back to normal after pain resolves with normal wound healing. However, persistent transmission of nociceptive signals leads to persistent central sensitisation through neuroplastic changes in the dorsal horn and higher centres, such as degeneration of inhibitory interneurons and remodelling of neuronal synapses by glial cells. 8 
Voltage-gated calcium channels
Voltage-gated and ligand-gated channels that are permeable to inorganic ions such as sodium, potassium, chloride, and calcium are essential for electrical activity of excitable cells such as neurons. 9 Calcium differs from the other ions as it also serves as an important signalling entity. Influx of calcium ions through high-voltage activated (HVA) calcium channels trigger a wide range of responses including gene transcription, neurotransmitter release, neurite outgrowth and activation of calcium dependent enzymes. 9 VGCCs are comprised of multiple subunits: a 1 , b, g, and a 2 d (Fig 1) . 10 The a1subunit allows entry of calcium ions. It comprises four homologous domains (IeIV), each of which contain six transmembrane helices (S1eS6). The extracellular a 2 subunit is attached to the d subunit via a disulfide linkage. The b subunit is entirely intracellular. VGCCs are classified into HVA (L-, P/Q-, N-, R-) and low-voltage activated (LVA; T-type) VGCCs. 11 Dorsal root ganglion cell bodies and presynaptic terminals that form synapses with dorsal horn neurons express increased density of N-type VGCCs. 10 The L-type channels are extensively found in both excitable and non-excitable tissues. Although less extensively studied, other subtypes may be involved in the pain pathway. 10 a2d subunit and pain
The auxiliary a 2 d and b subunits have four isoforms and enhance the plasma membrane expression and function of HVA calcium channels but not LVA channels. 12 The a2d-1 isoform that mediates the effects of gabapentinoids is present in the brain, skeletal, cardiac, and smooth muscle. a2d-2 and a2d-3 subunits are present in non-neuronal tissues in addition, whereas a2d-4 is expressed in retinal neurons and other non-neuronal tissues.
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The a2d-1 unit has widespread distribution in the mouse brain, especially in the cerebral cortex, hippocampus, and cerebellum.
12 Elevated concentration of a2d-1 subunit is clearly associated with augmented pain processing. DRG neurons show increased expression after peripheral nerve damage in animal models of neuropathic pain. 13e16 The peak expression of a 2 d-1 occurs 7 days after injury and takes several months to decline, with a temporal relationship with the onset and resolution of evoked behaviours. 15 Deletion of a2d-1 gene in mice models of neuropathic pain is associated with marked behavioural deficit in mechanical and cold sensitivity. Although both drugs are absorbed by facilitated transport through system L-neutral amino acid transporters, pregabalin is rapidly and completely absorbed with peak plasma concentrations within 1 h as opposed to 3 h with gabapentin.
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Unlike gabapentin, absorption of pregabalin is not saturable, with a linear pharmacokinetic profile and less variable bioavailability. 27 Although peak plasma concentrations of gabapentinoids are achieved within 1e3 h, peak cerebrospinal fluid (CSF) concentrations may take significantly longer, with a median time of 8 h. 28 They do not influence spinal neurotransmitter concentrations of glutamate, norepinephrine, substance P, and calcitonin gene-related peptide. 29 They are not metabolised by the liver and are excreted by the kidney with elimination half-lives of 6 h.
Effect on DRG neurons
Gabapentinoids are considered to exert their effects by inhibition of calcium currents. There was modest inhibition of calcium currents in medium sized and isolectin B4 (IB4) negative DRG neurons (small sized neurons that express neuropeptides projecting to lamina I and II) after prolonged incubation. 30 The acute application of low concentrations of
, which is a global VGCC blocker, was substantially more effective than gabapentinoids at inhibiting calcium currents in DRG neurons. If the classical mechanism is correct, Mn 2þ should have been even more effective in suppressing synaptic transmission in the dorsal horn. However, the effectiveness was reversed in the dorsal horn. Gabapentinoids suppressed excitatory synaptic transmission in the substantia gelatinosa neurons, whereas Mn 2þ had no effect. Clearly the moderate effect of gabapentinoids on calcium currents in DRG neurons alone could not explain its ability to reduce overall dorsal horn excitability. The reduction in neurotransmitter release because of gabapentin is therefore not entirely related to decreased calcium influx into presynaptic nerve terminals. Gabapentinoids have anti-allodynic rather than anaesthetic effect as not all DRG neurons are sensitive to gabapentionoids. 30 They preferentially affect medium sized neurons associated with Ad fibres that are often associated with nociceptive transmission and small IB4e neurons, with a complete lack of effect on the large and IB4þ neurons. Medium sized neurons and IB4e neurons project to excitatory neurons in the substantia gelatinosa, whereas large neurons associated with Ab fibres and IB4þ neurons project to inhibitory neurons.
30
Spontaneous firing of injured sensory neurons mediated by voltage-gated persistent sodium currents is implicated in the generation of neuropathic pain. Gabapentin decreased the amplitude of resonance and abolished the subthreshold membrane potential oscillations of A-type DRG neurons, in a chronic compressed dorsal root ganglion model. 25 
Effect on forward trafficking
The effects could be related to the forward trafficking of a 2 d to neurotransmitter release sites. a2d and b subunits could influence the HVA channel current density by increasing the expression of the pore forming a1 subunits. Gabapentinoids applied chronically could reduce calcium influx by suppressing the forward trafficking of a 2 d and calcium channels to the plasma membrane. 13 This could explain the significant effects on dorsal horn excitability in spite of the moderate effects on DRG neurons. The prolonged duration required for gabapentinoid action in vitro can then be explained as a consequence of the time required to transport recently synthesised pore- 50 The analgesic effect of gabapentin in neuropathic pain in a rat SNL model was reduced because of downregulation of astroglial glutamate-1 transporter in the locus coeruleus that reduced spinal noradrenergic inhibition but was reversed by oral valproate that is an inhibitor of histone deacetylase.
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Gabapentinoid effects on the affective component of pain can explain some of the analgesic effects. Positron emission tomography imaging indicated that the analgesic effect is mediated by suppressing medial prefrontal cortex, a brain area involved in the affective response to pain, with extensive connections to the limbic system. 52 The supraspinal mechanisms that modulate the affective-motivational qualities of pain require engagement of cortical endogenous opioid circuits that activate mesolimbic reward system involved in motivational aspects of pain behaviour. 53 
Effect on glutamate transport
Glutamate released by excitatory stimulation can accumulate extracellularly and cause excitotoxicity. Its concentrations are regulated by rapid removal by excitatory amino acid transporters (EAATs). 54 The glial cells take up glutamate that is metabolised to glutamine by glutamine synthase and is transported back to the neurons to replenish glutamate at the presynaptic membrane. 54 The EAAT1 and EAAT2 subtypes are more widely distributed in the neuronal tissue and are responsible for most of the glutamate uptake, the reduced expression of which contributes to the development of neuropathic pain. 55 All subtypes are expressed in the dorsal horn post synaptic membranes. 56 EAAT3, however, is less abundant as compared with the other subtypes and may act by influencing glutamate metabolism rather than neurotransmission. 56, 57 Pregabalin increased activity of EAAT3 in EAAT3-expressing oocytes in a dose-dependent manner, indicating that it may work by enhancing its trafficking to the plasma Effect of gabapentin on the internalisation of, and insertion into the plasma membrane of a2d-2 using an a-BBS-tagged a2d-2 subunit, and a fluorescent derivative of a- 59 This discrepancy may be related to the duration of exposure to the drug. Oocytes were exposed to pregabalin for 72 h as opposed to 3 min to gabapentin.
Time course of action of gabapentinoids
The actions of gabapentinoids in neuropathic pain take several hours to develop in vitro, but develop rapidly in vivo.
31,60
A likely explanation is that the in vitro studies are often done in uninjured animals whereas the in vivo studies are done on nerve-injured animals where a 2 d-1 has been already upregulated. 31 The effects are probably pronounced with increased expression of a 2 d-1 subunit with a higher rate of turnover of channel complexes that may be more vulnerable to gabapentinoids. 31 The rapid effects in vivo may be a result of rapid intracellular neuronal uptake that is absent in vitro. Substantia gelatinosa neurons obtained ex vivo after acute administration of intraperitoneal gabapentin in vivo in chronic constriction injury model were less excitable. 61 The rapid effects may be a result of effects on descending serotonergic and noradrenergic pathways and cortical mechanisms that might be unrelated to increased a 2 d-1 expression). Selected studies relating to analgesic mechanisms are described in Table 1 and Fig. 2 illustrates a summary of these mechanisms.
Effect on inflammation and postoperative pain models
Elevated proinflammatory cytokines are intimately associated with the development of neuropathic pain as part of the neuroinflammatory response and are inhibited by gabapentinoids. 62e66 Neuropathic and inflammatory pain differ in their aetiology but have common underlying mechanisms such as elevated tumour necrosis factor, Nav1.7, Nav1.8, glutamate, increased glial activation, and glutamate receptor function. 67 Animal studies of inflammatory pain induce inflammation after injection of a wide range of irritants and evaluate reflexive behavioural responses to thermal, mechanical, or electrical stimuli. Gabapentinoids are effective antinociceptives in most animal models of inflammatory pain (Table 2 ). However, some studies show limited effects.
84e87 Gabapentinoids reduce inflammatory mediators 69, 73, 78 and suppress dorsal horn activity 79, 83 but contrasting effects have been shown. 84 There is some evidence to support pre-emptive treatment. 72, 73, 85 Gabapentin was effective in suppressing single motor unit response but not windup, indicating a peripheral mechanism of action. 86 Mechanical and thermal responses were attenuated but reduction in activity was not improved acutely as compared with nonsteroidal anti-inflammatory drugs (NSAIDs). 87 Only chronic gabapentin had an effect on ambulatory-evoked pain. 76 The neurophysiology of incisional pain, however, is different from inflammatory and neuropathic pain with unique sensitisation processes. 88, 89 In the plantar incision model, a 1 cm longitudinal incision is performed through the glabrous skin, fascia, and plantar muscle of the rat hind paw. Short-lasting non-evoked guarding and longer lasting evoked pain-related behaviour are seen and used as surrogates for pain at rest and evoked pain (lasting several days to weeks) after surgery, respectively. Mechanical and heat but not cold hyperalgesia and anxiety behaviours develop after injury. The skin and muscle retraction injury model was developed to investigate prolonged pain after surgical incision. Gabapentinoids are effective in most animal models of postoperative pain (Table 2) . They demonstrate analgesic effects with synergistic effects in combination with opioids and NSAIDs. 90e97 They did not influence activity in a knee arthroplasty model but improved weight bearing when combined with opioids in an incision model.
92,98
Effects in human experimental pain models
Various models that explore the effect of gabapentinoids in human experimental pain have been described (Table 3 ). The Ultraviolet B (UVB) model is widely used for assessing efficacy of anti-inflammatory drugs. 115 Hyperalgesia is evoked by exposing an area of skin to an individualised dose of UVB. Gabapentinoids did not have any effect on heat pain perception and secondary hyperalgesia in this model of inflammation. 99, 100 The burn model is considered a model of inflammatory pain but both central and peripheral mechanisms are involved. 116 Gabapentin did not have any effect on heat pain detection threshold, pain during burn and secondary hyperalgesia. 101 However, it reduced area of secondary hyperalgesia after brief thermal stimulation of thigh. 102 The capsaicin model is used as a surrogate model of changes in neuropathic pain resulting in sensitisation. 117 Gabapentin had limited effects on measures of hyperalgesia in this model. 103e105 Capsaicin mediates hyperalgesia through effects on 
were found to contribute to this effect Collagen type II antibody modelgabapentin produced a preference in the early phase and a trend in the late phase, ketorolac ineffective Glucose-6-phosphate isomerase modelboth gabapentin and ketorolac produced a preference for the drugpaired compartment in the early phase. Gabapentin, but not ketorolac, resulted in a place preference during late phase
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Fig 2.
Gabapentinoids inhibit calcium mediated neurotransmitter release through effects on a2d-1 subunits. They inhibit forward trafficking of a2d-1 from the dorsal root ganglion, their recycling from endosomal compartments, thrombospondin mediated processes and stimulate glutamate uptake by excitatory amino acid transporters (EAAT). Mechanisms not directly related to neurotransmitter release at dorsal horn include inhibition of descending serotonergic facilitation, stimulation of descending inhibition, anti-inflammatory actions and influence on the affective component of pain. 108, 109 Contrasting effects were also seen after sural nerve stimulation. 108, 110 The continuous electrical stimulation model induces both central sensitisation and continuous C-fibre mediated pain. Gabapentin increased the current strength required to induce pain and reduced area of secondary hyperalgesia but did not influence pain detection threshold in area of hyperalgesia. 111 Gabapentinoids had modest effects on the pain tolerance threshold to single electrical stimulus. 99, 111 Chemical stimulation of muscle by i.m.
injection of hypertonic saline mimics musculoskeletal pain resulting in deep and diffuse pain as a result of activation of Cfibres. 117 Contrasting effects were seen with gabapentin. 107, 111 Gabapentin reduced pain intensity in the cold pressor test model but only in combination with morphine unlike pregabalin that was effective alone. 99, 112 Conditioned pain modulation, which is a measure of endogenous pain inhibitory pathways, was not influenced. 99, 113 Pregabalin enhanced both opioid analgesia and respiratory depression. 114 
Discussion
Gabapentinoids certainly act on a2d receptors and attenuate the enhanced dorsal horn excitability. It is, however, evident that various effects not directly related to neurotransmitter release at pre-synaptic terminals also contribute to analgesia. Battery of tests eliciting cutaneous electrical mechanical and thermal pain and included a UVB model, the thermal grill illusion, and a paradigm of CPM (n¼16) Pregabalin 300 mg, pain measurements at baseline and up to 10 h post [ (PTT) for single electrical stimulus (10.8%), mechanical pain (14.1%), cold pressor (46.4%) and normal skin heat pain detection threshold (4.1%).
No effect on single electrical PDT, no effect on repeat electrical PTT or PDT. No changes to thermal grill and CPM. No effect of pregabalin on PDT after UVB Dizziness (56%), somnolence (31%) and nausea (31%) with pregabalin. Gustorff and colleagues 100 Double-blind, active placebo-controlled, four-way cross-over design (n¼16) Burn injury (UVB) model; gabapentin 600 mg, burn injury 20 h prior, comparison with remifentanil; PDT and PTT to heat in area of primary hyperalgesia and control, area of secondary hyperalgesia to pinprick
Gabapentin had no noticeable effect on heat PDT and PTT and the area of secondary hyperalgesia
Werner and colleagues 101 Double-blind, randomised, placebo-controlled cross-over study (n¼22) Burn injury model; gabapentin 1200 mg or placebo given on two separate days, burn injury after 3 h Y Mechanical allodynia in burn area but no significant reduction in heat pain threshold, pain during the burn, mechanical pain in area of secondary hyperalgesia, no effect in normal skin Dirks and colleagues 102 Double-blind, randomised, placebo-controlled cross-over study (n¼25) Heat capsaicin sensitisation model, brief thermal sensitisation on thigh, long thermal stimulation; gabapentin 1200 mg; in primary hyperalgesia area PDT to heat; area of secondary hyperalgesia to pinprick and allodynia to brushing 
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The absence of effects in spinalised animals supports the role of supraspinal mechanisms. 85 Elevated concentration of CSF norepinephrine after preoperative gabapentin indicates that some effects are mediated by descending noradrenergic inhibition. 94 However, there was no effect on conditioned pain modulation that is a measure of inhibitory influences. 99, 113 The interaction of gabapentinoids with serotonin pathways is complex with permissive conditions for their effects dependent on the up-regulation of serotonergic facilitatory systems. 47, 48 The role of serotonin in pain has not been fully elucidated with both facilitatory and inhibitory influences on nociception depending on the presence of injury. 118 This may explain the state dependent actions of gabapentinoids that have effects only in the presence of injury. 86, 101 The influence on affective component of pain is independent of analgesic effects. 53 Pregabalin has well known anxiolytic effects that may have positive effects on postoperative rehabilitation. 119, 120 The discrepancy between the acute effects in vivo as opposed to the prolonged duration of exposure required in vitro can be explained conceptually on the greater sensitivity of elevated levels of a2d1 in nerve injury models to gabapentinoid action, rapid uptake by in vivo models, antiinflammatory actions and by modulation of descending influences and the affective component of pain.
There are no studies looking at the role of a2d in inflammation and incisional pain models. Elevated levels of a2d-1 may be specific to neuropathic pain. Gabapentinoids seem to be effective antinociceptives in most animal models of inflammatory pain but prolonged administration may be required to achieve improved ambulation. 76 This explains the lack of improvement in activity in a model of complete Freund's adjuvant-induced arthritis. 87 Gabapentin was effective in all animal models of postoperative pain with synergistic effects with opioids. However, the difference in neurobiology of nociceptive systems between species limits the extrapolation of findings from animal studies to humans. 121, 122 The few studies that have explored the effects in human models of inflammatory pain do not show convincing evidence of benefit. 99e101 It is difficult to explain the contrasting effects on pain induced by chemical stimulation of muscles and repetitive electrical stimulation. The lack of effect on secondary hyperalgesia induced by continuous electrical stimulation may be a result of the higher strength of current required in the premedicated group. 111 The lack of effect of gabapentin as compared with pregabalin in the cold pressor model may be a result of differences in pain assessment methods. 114 There are no studies looking at effects in human models of postoperative pain. However, the effects on animal models suggest that gabapentinoids could contribute to multimodal analgesia. Several meta-analyses have shown a modest reduction in the use of opioids after surgery. 123e127 However, the quality of the trials is moderate to very low. 4 There is conflicting evidence with regards to the timing (preoperative or postoperative) and the optimal dose. 3 Although peak CSF concentrations are achieved at a median time of 8 h, the relevance is uncertain, as pregabalin in clinical doses does not influence spinal neurotransmitter concentrations. 29 The optimal dose has not been defined as the few studies that have attempted to 76 This suggests that continued use is necessary for any potential benefit. This approach might, however, increase the risk of adverse effects such as dizziness and increased sedation. 4 Gabapentinoids have synergistic analgesic effects with opioids but also enhance opioid-induced respiratory depression. 114 Significant number of healthy subjects in experimental studies experienced adverse effects, particularly with increasing dosage. 99, 103, 104, 108, 109 Gabapentinoids are often utilised in enhanced recovery pathways, particularly for hip and knee replacement surgery. These procedures are often performed in the elderly, who may be more vulnerable to the potential side effects of gabapentinoids. 129 It therefore makes intuitive sense to tailor the use of gabapentinoids to the clinical situation. Perioperative use is appropriate in patients having 'pro-nociceptive surgery', such as spine surgery that may be associated with nerve damage. 130 Patients on high dose opioids who are tolerant to their effects could benefit from even the modest effects of gabapentinoids. They might be helpful in situations where even marginal additional improvements in analgesia could potentially influence outcome (e.g. multiple rib fractures resulting in impaired ventilation as a result of poor pain control).
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The evidence for the role of gabapentinoids in prevention of chronic pain is limited. They have modest analgesic effects in chronic neuropathic pain with numbers needed to treat of 7.7 (6.5e9.4) for pregabalin and 7.2 (5.9e9.2) for gabapentin. 132 A Cochrane review suggested that gabapentinoids do not have a preventative role. 83 Recent systematic reviews have differing conclusions with regards to effectiveness in preventing persistent pain. 126, 133 The lack of evidence may be because of inadequate sample size and poor trial designs. 134 It is not surprising, however, that a clear benefit in terms of prevention of chronic pain has not been found as, although a2d-1 is required for rapid development of hypersensitivity, its absence does not prevent sensitisation. 17 This suggests that there are other mechanisms involved that contribute to the development of hypersensitivity. It is possible that these subunits are no longer upregulated in chronic pain, resulting in lack of efficacy. 135 The poor efficacy in chronic pain might be a result of differential upregulation of splice variants with reduced affinity to gabapentin. 136 Downregulation of glutamate transporter-1 can reduce long-term efficacy, but addition of valproate can restore efficacy. 51 Translational studies studying the effects of analgesics in human models of postoperative pain are required to bridge the gap between human clinical studies and animal models. A human surrogate model of postoperative pain has been described. 137 There is no information regarding persistence of a2d upregulation in both animal and human studies. Future studies could focus on persistence of a2d and any possible correlation between the efficacy of gabapentinoids and concentrations of a2d and the presence of variants. This could allow targeted treatments with gabapentinoids for neuropathic pain and reduce the risk of exposing patients who might otherwise not benefit, to adverse effects. The potential of valproate to restore the efficacy of gabapentinoids needs to be explored. Well designed, large-scale trials are required to evaluate the effects on development of persistent pain.
Conclusion
The actions of gabapentinoids cannot be attributed solely to blockade of calcium channels. A more accurate description of their mechanism is depression of presynaptic excitatory input onto dorsal horn neurons through interactions with a2d-1 subunits that are upregulated after injury. They inhibit forward trafficking of a2d-1 from the dorsal root ganglion, their recycling from endosomal compartments, thrombospondin mediated processes and stimulate glutamate uptake by EAATs. Mechanisms not directly related to neurotransmitter release at dorsal horn include inhibition of descending serotonergic facilitation, stimulation of descending inhibition, anti-inflammatory actions and influence on the affective component of pain. Gabapentinoids are effective analgesics in most animal models of inflammation and postoperative pain but effects in human models are variable. The risk of adverse effects is increased with increasing dosage. In situations where the riskebenefit balance is in favour of starting gabapentinoids, they should be started pre-emptively and continued throughout the perioperative period. 
